Perkin Elmer

PerkinElmer is a global life sciences company uniquely positioned to bring instruments and software solutions to enable comprehensive imaging & detection solutions for your preclinical research. Our Quantum GX microCT imaging system combines high resolution microCT imaging with high-speed, low dose CT scanning across multiple species, ideal for bone and tissue research. When coupled with AccuCT™, our automated, advanced bone analysis software, researchers can perform ASBMR bone morphometry and BMD analysis with just a few clicks.  Stop by booth 16 and learn  how PerkinElmer preclinical solutions can work for you.

IDS

Immunodiagnostic Systems Limited is a leading in-vitro diagnostic solution provider to the clinical laboratory market. Our immunoassay portfolio is available for use on our fully-automated IDS-iSYS Multi-Discipline Automated System, or as stand-alone manual assay kits. This complete offering meets the needs of both clinical and research laboratories of all types and sizes with their diagnostic testing requirements. Immunodiagnostic Systems offers a unique and full panel of bone turnover markers, for the measurement and monitoring of bone resorption and formation markers which provide highly accurate and reliable results. For more product information visit us on stand 15 or go to www.idsplc.com

Bruker

Offering the largest range of Preclinical Imaging systems, with an unmatched 9 in-vivo modalities, Bruker is committed to supporting the scientific community with high-end instruments dedicated to disease research, translational science and Molecular Imaging.

Benefitting from more than 5 decades of passionate innovation, Bruker customers enjoy a vast portfolio of possibility; from a single source they have endless opportunities for combining multiple modalities for seamless workflow and higher productivity.  Our non-invasive in-vivo imaging modalities are designed to deliver greater scientific insight based on animal-centric solutions.

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

ECTS-Eli Lilly Healthcare Provider Scholarships 2017

Focused on providing financial assistance for clinicians, this scholarship programme, funded by Eli Lilly, is designed to support the professional development of clinicians, through participation at ECTS 2017 Congress.

Successful recipients will receive a complimentary registration at the ECTS 2017 Congress and a travel grant of up to €500.

Read here all details about eligibility criteria and application details.

CEE Osteoporosis Summit Working Group

Preliminary Programme

Lectures

  • Welcome and background of the CEE meetings;
  • Standards of diagnosis and therapy of Osteoporo sis;

Debates:

30 minutes /3 personal communications/ 3 minutes

  • Strenghts and limitations of biochemical markers in the diagnosis and treatment of Osteoporosis,
  • Strenghts and limitations of the generation of epidemiologic fracture data in the CEE countries,
  • Strenghts and limitations of diagnosis and treatment in male Osteoporosis

Registration

Registration is complimentary for all Pre-Congress Delegates, but pre-registration is required. You can register here

FishBone Workshop

About the FishBone Workshop

Zebrafish, medaka, and other laboratory fish models hold unique potential to open ‎powerful avenues for skeletal research that are challenging in other vertebrate systems. However, ‎the use of fish models for bone biomedical research has yet to be widely established. Modern technologies have ‎brought forth new opportunities to identify genetic and phenotypic similarities between fish and mammalian skeletons, as well as translate across fish and human bone physiologies. These efforts by the community may be greatly aided by bringing together established and potential fish users with bone researchers from different disciplines.
The mission of FishBone is to bring together basic scientists and clinical researchers from the bone biomedical community together with fish skeletal biologists to facilitate cross-talk, establish foundations, and develop new experimental models of skeletal health.

To this end, FishBone, in association with the Interdisciplinary Approaches in Fish Skeletal Biology Association (IAFSB), is happy to announce FishBone 2017 to be held on May 12th, 2017 in Salzburg Austria, in conjunction with the Pre-congress Programme of the 44th European Calcified Tissue Society (ECTS) Congress.

FishBone participants who attend the ECTS meeting will have the option of presenting their work within a dedicated poster cluster at the ECTS meeting on fish skeletal models.
For more information about FishBone 2017 please visit the workshop website.

Abstract submission for FishBone 2017 is now open. Abstracts are due February 22, 2017.

Online Submission

For abstract submission, download the template and follow the instructions. Save the document as a .doc file using the following naming convention:
Last name of the first author + “_FishBone2017.doc” (for example: LastName_FishBone2017.doc).
Email the file to fishbone@uw.edu. Please be sure to mark whether you prefer an oral presentation or poster presentation at the FishBone Workshop, and also whether you would like your abstract to be considered for poster presentation at ECTS, within the abstract file.

Topics

  • Fish models of musculoskeletal disease
  • Skeletal development
  • Bone regeneration
  • Bone/muscle adaptation
  • Technologies for bone imaging
  • Genetic engineering in fish

Format
The format of FishBone encourages interaction between established and potential fish users and ‎bone researchers from different disciplines. All presenters are encouraged to provide back-ground to bring participants to a basic level of understanding, as well as to present new data.

Organizing Committee

Antonella Forlino
David Karasik
Ronald Kwon
Matthew Harris

Registration

You can register to the FishBone 2017 Workshop here

Sponsors

The organizers of FishBone would like to thank the following sponsors for their support:

Scanco Medical

 



Bruker

 

 

 

 

German Language Course on Biomarkers (for D-A-CH countries)

Thema des Kurses:

Knochenstoffwechselmarker (bone turnover markers, BTM) werden schon lange als diagnostische Tests für metabolische Knochenerkrankungen eingesetzt. In den letzten 20 Jahren wurden deutlich spezifischere Analyten etabliert, die für die Osteoporosediagnostik, aber besonders auch für das Therapiemonitoring sinnvoll sind. Dieser Kurs soll ein Basiswissen zur klinischen Verwendung von Knochenstoffwechselmarkern vermitteln.

Zielpublikum:

Dieser eintägige Kurs ist offen für alle klinisch tätigen Ärztinnen und Ärzte (aus Endokrinologie, Rheumatologie, Geriatrie, klinischer Chemie, Unfallchirurgie und/oder Orthopädie), Laborfachkräfte und Pflegepersonen, die in das klinische Management von Risikopersonen für osteoporotische Frakturen eingebunden sind.
Zielsetzungen:

Am Ende des Kurses sollten die Teilnehmer

  • die Prozesse des Knochenumbaus verstehen und wie sie durch Knochenstoffwechselmarker untersucht werden können
  • die Rolle der Knochenstoffwechselmarker in Diagnose und Therapieüberwachung in einer Reihe von Knochenerkrankungen wie Osteoporose, chronischen Nierenerkrankungen, Mb. Paget, Osteomalazie, kortikoidinduzierter Osteoporose und primärem Hyperparathyreoidismus einschätzen
  • mit bewährten Methoden in der klinischen Anwendung von Knochenstoffwechselmarkern in der Praxis anhand zahlreicher Fallbeispiele gut umgehen können

Registration:

Sie können sich hier registrieren

Programm:

ab 08:30 Uhr    Registrierung der TeilnehmerInnen

09:00 Uhr         Begrüßung und Einführung durch Prof. Eastell und Prof. Obermayer-Pietsch

09:15 – 10:45 Uhr     Block I

1. Knochenbiologie und Remodelling
2. Prakt. Aspekte der Messung und Selektion von Biomarkern
3. Ursachen der Variabilität von Knochenbiomarkern
Vortragende: Meier, Obermayer-Pietsch, Siggelkow, Wüster

11:05 – 11:30 Uhr     Kaffeepause

11:30 – 13:00 Uhr     Block II

4. Verwendung von Biomarkern bei  Osteoporose
5. Metabolische Knochenerkrankungen
6. Knochenstoffwechsel bei Niereninsuffizienz
Vortragende: Meier, Obermayer-Pietsch, Siggelkow, Wüster

13:00 – 13:40 Uhr     Mittagessen

13:40 – 14:30 Uhr     Block III

7. Fallbeispiele und Anwendungen, alle

anschließend Testat, alle

Seminarende ca. 15:00 Uhr

15:30 – 15:50 Kaffee und Verabschiedung

ECTS – Mellanby Course on Bone Biomarkers

Course overview:

Bone Turnover Markers (BTM) have long been used as diagnostic tests for metabolic bone diseases. In the past 20 years, markers that are more specific to bone have been introduced and have been found to be useful in osteoporosis, particularly for monitoring treatment. This course aims to provide a background to the clinical use of bone turnover markers.

Target audience:

This day-long course is open to clinicians (e.g. endocrinology, rheumatology, care of the elderly and clinical chemistry), laboratory scientists and nurses involved in the clinical management of patients at risk of osteoporotic fractures.

Objectives:

At the end of the course, participants should:

  • understand the process of bone remodelling and how this can be studied using BTM
  • appreciate the methods used for measuring BTM and their sources of variability
  • be able to identify the role of BTM in the diagnosis and monitoring of bone diseases in a number of clinical settings including; osteoporosis, chronic kidney disease, Paget’s disease, osteomalacia,GIOP and PHPT.
  • be familiar with best practice in the clinical use of BTM

Registration:

You can register to the ECTS-Mellanby Training Course here

Programme:

08:45-09:30 REGISTRATION AND COFFEE

09:30-09:35 BONE TURNOVER MARKERS: AN INTRODUCTION, Richard Eastell (Sheffield, UK)

09:35-10:05 BONE REMODELLING AND THE INTERPRETATION OF BONE TURNOVER MARKER (BTM) RESULTS, Nuria Guanyabens (Barcelona)

10:35-11:05    SOURCES OF VARIABILITY IN BTM, Jennifer Walsh (Sheffield, UK)

11:05-11:30    COFFEE BREAK

11:30-12:00    USE OF BTM IN OSTEOPOROSIS: SHARED CARE PROTOCOLS IN PRIMARY CARE, Richard Eastell (Sheffield, UK)

12:00-13:00    INTERACTIVE WORKSHOPS

GROUP A: PROTOCOLS AND CASE EXAMPLES FOR THE USE OF BTM IN OSTEOPOROSIS PRACTICE, Jennie Walsh  (Sheffield, UK) and Eugene McCloskey

GROUP B: USING BTM FOR OSTEOPOROSIS TREATMENT: RESEARCH APPLICATION, Richard Eastell (Sheffield, UK) and Nuria Guanyabens (Barcelona)

13:00-13:40    LUNCH

13:40-14:30    METABOLIC BONE DISEASES IN ADULTS (Pagets, Osteomalacia, GIOP & PHPT), Eugene McCloskey (Sheffield, UK)

14:30-15:00    METABOLIC BONE DISEASE OF CHRONIC KIDNEY DISORDER, Barbara Obermeier-Pietsch (Graz, Austria)

15:00-15:30    WHEN AND HOW TO USE BONE HISTOMORPHOMETRY, Erik Eriksen (Oslo, Norway)

15:30-15:50    COFFEE BREAK

15:50-16:50    INTERACTIVE WORKSHOPS

GROUP A: PROTOCOLS FOR THE USE OF BTM IN OSTEOPOROSIS PRACTICE, Jennie Walsh (Sheffield, UK) and Erik Eriksen (Oslo, Norway)

GROUP B: USING BTM IN METABOLIC BONE DISEASE, Eugene McCloskey (Sheffield, UK) and Nuria Guanyabens (Barcelona)

17:10-17:30    EXPERT PANEL: QUESTIONS AND ANSWERS, All speakers

17:30        CLOSE OF DAY

Disclaimer

1. Referrals and links

The author is not responsible for any contents linked or referred to from his pages – unless he has full knowledge of illegal contents and would be able to prevent the visitors of his site from viewing those pages. If any damage occurs by the use of information presented there, only the author of the respective pages might be liable, not the one who has linked to these pages. Furthermore the author is not liable for any postings or messages published by users of discussion boards, guest books or mailing lists provided on his page.

2. Copyright

The author intended not to use any copyrighted material for the publication or, if not possible, to indicate the copyright of the respective object.

The copyright for any material created by the author is reserved. Any duplication or use of objects such as images, diagrams, sounds or texts in other electronic or printed publications is not permitted without the author’s agreement.

3. Privacy policy

The use of published postal addresses, telephone or fax numbers and email addresses for marketing purposes is prohibited, offenders sending unwanted spam messages will be punished.

3.1 Note on data protection and cookie usage

This website makes use of Google Analytics, a web analytics service provided by Google, Inc. („Google“). Google Analytics uses „cookies“, which are text files placed on your computer to help the website analyze how visitors use the site. The information generated by the cookie about your use of the website (including your IP address) will be transmitted to and stored by Google on servers in the United States. Google will use this information for the purpose of evaluating your use of the website, compiling reports on website activity for website operators and providing other services relating to website activity and internet usage. Google may also transfer this information to third parties where required to do so by law, or where such third parties process the information on Google’s behalf. Google will not associate your IP address with any other data held by Google. You may refuse the use of cookies by selecting the appropriate settings on your browser, however please note that if you do this you may not be able to use the full functionality of this website. By using this website, you consent to the processing of data about you by Google in the manner and for the purposes set out above.

4. Legal validity of this disclaimer

This disclaimer is to be regarded as part of the internet publication which you were referred from. If sections or individual terms of this statement are not legal or correct, the content or validity of the other parts remain uninfluenced by this fact.
Please click or use the back-button of your browser to return to the original page!

1 2 3 4 6